{
    "title": "FDA panel backs first-in-class cholesterol drug",
    "url": "https://www.dailymail.co.uk/wires/ap/article-3117430/FDA-panel-backs-class-cholesterol-drug-Sanofi.html",
    "date": "2015-06-09",
    "keywords": [
        "drug",
        "cholesterol",
        "heart",
        "panel",
        "regeneron",
        "ldl",
        "gmt",
        "june",
        "approval",
        "sanofi",
        "ability",
        "university",
        "fda",
        "population",
        "class",
        "disease",
        "group",
        "percent",
        "press",
        "email",
        "gaithersburg",
        "md",
        "health",
        "tuesday",
        "caveat",
        "attacksthe",
        "expert",
        "vote",
        "food",
        "administration",
        "praluentbut",
        "development",
        "number",
        "disorder",
        "side",
        "optimism",
        "outcome",
        "study",
        "philip",
        "sanger",
        "stanford",
        "drugif",
        "proposedpraluent",
        "part",
        "treatment",
        "amgen",
        "substance",
        "pcsk9",
        "blood",
        "blockbuster",
        "meeting",
        "uncertainty",
        "control",
        "prevention",
        "risk",
        "cause",
        "death",
        "york",
        "highrisk",
        "statin",
        "family",
        "disorderi",
        "equation",
        "consumer",
        "representativekey",
        "decision",
        "benchmark",
        "lipitor",
        "zocorbut",
        "attack",
        "stroke",
        "predictor",
        "today",
        "hiatt",
        "school",
        "medicine",
        "drugdespite",
        "endorsement",
        "company",
        "outcomethis",
        "product",
        "promise",
        "bill",
        "vice",
        "president",
        "stock",
        "trading",
        "announcement",
        "sanofis"
    ],
    "category": [
        "wires",
        "ap"
    ]
}